Winner of the Best Early Stage Biotech: Immunovaccine @ViE Awards #wvcusa

best early stage biotech immunovaccine world vaccine congress

The Best Early-Stage Vaccine Biotech category was open to an international array of spin-outs and Early-stage Biotechs.

The criteria used to judge this category will be as follows:

  • Ability to move the business from early stage to a more mature company
  • Quality and diversity of the vaccine pipeline and candidates 
  • Advancements in taking a new product to market or through clinical stages
  • Meaningful licensing or partnership deals 
  • Securing significant new funds for growth

Winner: Immunovaccine


Judges specific comments on the winner included:

1.    Excellent early clinical trial results surrounding their powerful delivery platform, their product has such great potential to be a building block for so many diverse vaccines.
2.    This company has established key collaborations with high profile partners to potentially expand the product pipeline in infectious disease, addiction and biodefense.
3.    Its also worth noting in the wider industry vote, although not decisive, this company gained 45% of the 698 votes cast for this category


Well done Immunovaccine !


Highly Regarded' recommendation: Inovio Pharmaceuticals for their broad pipeline development progress in 2011/2012. 

Leave a Reply

Your email address will not be published. Required fields are marked *